Testing done after CHCP demonstrated a 92-99% reduction of viability across seven breast cancer cell lines. The first FDA-approved clinical trial is underway at Sheba Medical Center and Rush University Medical Center.
At present, there are over 3.5 million women in the United States living with breast cancer. Additionally, in the US alone, 2020 statistics estimate that 276,480 new cases of invasive breast cancer in women are expected to be diagnosed, and more than 42,000 deaths from breast cancer are anticipated. New approaches to therapy are necessary, and testing done after treatment with Canady Helios™ Cold Plasma Scalpel (CHCPS) has shown encouraging results as an innovative breast cancer treatment.
The Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS), working in conjunction with US Medical Innovations, LLC (USMI), recently announced that Canady Helios™ Cold Plasma Scalpel (CHCPS) has been used effectively to inhibit cell viability in breast cancer molecular subtypes.
An article published in the journal of Clinical Plasma Medicine reported that in vitro testing done 48 hours after treatment with Canady Helios™ Cold Plasma Scalpel showed a 92-99% reduction of viability across seven different cell lines of breast cancer.
As a result of this milestone research, JCRI-ABTS is planning to develop the first plasma immunotherapy drug for solid tumors in early 2021. Animal studies will follow, and then a phase I clinical trial is scheduled for later next year.
Presently, Sheba Medical Center and Rush University Medical Center (Chicago, IL) are hosting the first FDA-approved clinical trial to assess CHCPS for the treatment of recurrent stage IV solid tumors; the trial is being conducted by JCRI-ABTS and USMI. Prior to the Phase I clinical trial, the use of CHCPS in humans was limited to FDA-approved Expanded Access cases. Currently, the most recent case (treated 14 months ago) remains tumor-free. No adverse events have been noted in the IDE clinical trial and expanded access cases.
“We are very excited about the results of this new report, particularly the results pertaining to the Triple-Negative Breast Cancer (TNBC) cell lines,” said Dr. Canady. “TNBC patients do not respond to endocrine therapies or HER2-targeted therapies, such as trastuzumab. Compared to other breast cancer phenotypes, TNBC has a significantly higher rate of death, recurrence and risk of metastatic spread to the lungs, liver, and brain despite adjuvant chemotherapy.”
The JCRI-ABTS team recently achieved two additional breakthroughs that will be submitted for publication this year: Their first study showed a 95-100% cell death (apoptosis) of all breast cancer lines, and their second study identified a survival gene for breast cancer following CHCPS treatment.